Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31192804 | 0.88 | CYP1A2 (0.42) | CYP1A2MAPTALDH1A1KDM4ERECQL | |
| SCHEMBL6335694 | 0.86 | ALDH1A1 (0.37) | CYP1A2MAPTALDH1A1LMNA | |
| SCHEMBL31582903 | 0.81 | LMNA (0.38) | CYP1A2MAPTALDH1A1KDM4ERECQL | |
| SCHEMBL6336215 | 0.77 | ALDH1A1 (0.36) | CYP1A2MAPTALDH1A1LMNA | |
| SCHEMBL6335267 | 0.75 | CYP1A2 (0.42) | CYP1A2ALDH1A1 | |
| SCHEMBL6341505 | 0.74 | CCNA2 (0.43) | CYP1A2MAPTALDH1A1 | |
| SCHEMBL10739766 | 0.74 | ALDH1A1 (0.37) | MAPTALDH1A1 | |
| SCHEMBL6344025 | 0.74 | CCNA2 (0.43) | MAPTALDH1A1LMNA | |
| SCHEMBL28832795 | 0.72 | CYP1A2 (0.44) | CYP1A2MAPTALDH1A1LMNA | |
| SCHEMBL6014976 | 0.71 | CYP1A2 (0.52) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2734521-B1 | TETRAHYDROPYRIDO-PYRIDINE AND TETRAHYDROPYRIDO-PYRIMIDINE COMPOUNDS AND USE THEREOF AS C5A RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2017-05-10 | — | — | EP | disclosed |
| US-9505755-B2 | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5A receptor modulators | NOVARTIS AG (CH) | 2016-11-29 | — | — | US | disclosed |
| US-20140349995-A1 | TETRAHYDROPYRIDO-PYRIDINE AND TETRAHYDROPYRIDO-PYRIMIDINE COMPOUNDS AND USE THEREOF AS C5A RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2014-11-27 | — | — | US | disclosed |
| US-8846656-B2 | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators | NOVARTIS AG (CH) | 2014-09-30 | — | — | US | disclosed |
| EP-2734521-A1 | TETRAHYDROPYRIDO-PYRIDINE AND TETRAHYDROPYRIDO-PYRIMIDINE COMPOUNDS AND USE THEREOF AS C5A RECEPTOR MODULATORS | Novartis AG (CH) | 2014-05-28 | — | — | EP | disclosed |
| US-20130184253-A1 | TETRAHYDROPYRIDO-PYRIDINE AND TETRAHYDROPYRIDO-PYRIMIDINE COMPOUNDS AND USE THEREOF AS C5A RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2013-07-18 | — | — | US | disclosed |
| WO-2013016197-A1 | TETRAHYDROPYRIDO-PYRIDINE AND TETRAHYDROPYRIDO-PYRIMIDINE COMPOUNDS AND USE THEREOF AS C5A RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2013-01-31 | — | — | WO | disclosed |
| US-7470713-B2 | Imidazole based kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-7312215-B2 | Benzimidazole C-2 heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312215-B2 | Benzimidazole C-2 heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312215-B2 | Benzimidazole C-2 heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1651611-A2 | BENZIMIDAZOLE C-2 HETEROCYCLES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005021510-A2 | BENZIMIDAZOLE C-2 HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050054655-A1 | Benzimidazole C-2 heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349995-A1 | TETRAHYDROPYRIDO-PYRIDINE AND TETRAHYDROPYRIDO-PYRIMIDINE COMPOUNDS AND USE THEREOF AS C5A RECEPTOR MODULATORS | C5AR1, C3AR1, C5AR2 | CYP1A2 940/4885MAPT 4166/4885ALDH1A1 2058/4885 |
| US-20050054655-A1 | Benzimidazole C-2 heterocycles as kinase inhibitors | CDK2, ERBB2, ABL1 | CYP1A2 1249/4885MAPT 4312/4885ALDH1A1 2026/4885 |
| US-20130184253-A1 | TETRAHYDROPYRIDO-PYRIDINE AND TETRAHYDROPYRIDO-PYRIMIDINE COMPOUNDS AND USE THEREOF AS C5A RECEPTOR MODULATORS | C5AR1, C3AR1, C5AR2 | CYP1A2 933/4885MAPT 4178/4885ALDH1A1 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.